Download full-text PDF |
Source |
|---|---|
| http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5621713 | PMC |
| http://dx.doi.org/10.21542/gcsp.2017.2 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Cold shock domain-containing protein E1 is a posttranscriptional regulator of the LDL receptor.
Sci Transl Med
September 2022
Department of Medicine, University of California, San Francisco, San Francisco, CA 94143, USA.
Article Synopsis
- * They discovered that the protein CSDE1 significantly impacts LDLR regulation and cholesterol management in liver cells, showing effects comparable to statins and PCSK9 inhibitors.
- * The research suggests that targeting CSDE1 could be a promising therapy for preventing cardiovascular disease, and the study's approach may help identify potential treatments for other health issues as well.
[From statin revolution to gene silencing therapy: 50 years of evolution in the treatment of hypercholesterolemia].
G Ital Cardiol (Rome)
July 2022
Dipartimento di Scienze Biomediche Avanzate, Università degli Studi "Federico II", Napoli - Mediterranea Cardiocentro, Napoli.
The last 50 years have experienced a rapid evolution in the development of lipid-lowering agents to reduce low-density lipoprotein cholesterol levels. This significant advance in medicine has not occurred without debate. Whether lowering blood cholesterol levels was beneficial has remained one of the most controversial issues during the past 50 years.
View Article and Find Full Text PDFLipid-lowering therapy: Guidelines to precision medicine.
Clin Chim Acta
March 2021
Department of Cardiology, The Xiamen Cardiovascular Hospital of Xiamen University, Xiamen, Fujian, China. Electronic address:
Dyslipidemia is correlated with a series of health problems, such as obesity, insulin resistance, and the development of cardiovascular disease (CVD). Currently, accumulating evidence sheds light on the fact that β-hydroxy β-methylglutaryl-CoA reductase inhibitors, named statins, could lower circulating lipid-density lipoprotein cholesterol (LDL-C) and represent a revolution for the prevention of metabolic disorder diseases. In addition, statins remain the cornerstone of LDL-C-lowering treatments, together with ezetimibe and bile acid sequestrants, which are used either in combination with statins or as monotherapies in the case of statin intolerance or side effects.
View Article and Find Full Text PDFLow-density lipoprotein cholesterol lowering treatment: the current approach.
Lipids Health Dis
May 2020
Department of Internal Medicine, "Carol Davila" University of Medicine and Pharmacy, Clinical Emergency Hospital of Bucharest, 8 Eroii Sanitari Blvd, 050474, Bucharest, Romania.
In the last 50 years, several clinical and epidemiological studies during have shown that increased levels of low-density lipoprotein cholesterol (LDLc) are associated with the development and progression of atherosclerotic lesions. The discovery of β-Hydroxy β-methylglutaryl-CoA reductase inhibitors (statins), that possess LDLc-lowering effects, lead to a true revolution in the prevention and treatment of cardiovascular diseases. Statins remain the cornerstone of LDLc-lowering therapy.
View Article and Find Full Text PDFFragment-based design of small molecule PCSK9 inhibitors using simulated annealing of chemical potential simulations.
PLoS One
March 2020
Conifer Point Pharmaceuticals, Doylestown, PA, United States of America.
PCSK9 is a protein secreted by the liver that binds to the low-density lipoprotein receptor (LDLR), causing LDLR internalization, decreasing the clearance of circulating LDL particles. Mutations in PCSK9 that strengthen its interactions with LDLR result in familial hypercholesterolemia (FH) and early onset atherosclerosis, while nonsense mutations of PCSK9 result in cardio-protective hypocholesterolemia. These observations led to PCSK9 inhibition for cholesterol lowering becoming a high-interest therapeutic target, with antibody drugs reaching the market.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!